Menu Search
Equities

Checkpoint Therapeutics Inc

CKPT:NAQ

Checkpoint Therapeutics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)3.37
  • Today's Change-0.09 / -2.60%
  • Shares traded718.20k
  • 1 Year change+81.18%
  • Beta1.2658
Data delayed at least 15 minutes, as of Nov 08 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Checkpoint Therapeutics Inc had revenues fall -46.35% from 192.00k to 103.00k, though the company grew net income from a loss of 62.62m to a smaller loss of 51.85m.
Gross margin--
Net profit margin-54,444.87%
Operating margin-45,501.28%
Return on assets-606.33%
Return on equity--
Return on investment--
More ▼

Cash flow in USDView more

In 2023, cash reserves at Checkpoint Therapeutics Inc fell by 7.14m. Cash Flow from Financing totalled 40.45m or 39,271.84% of revenues. In addition the company used 47.59m for operations while cash used for investing totalled .
Cash flow per share-1.45
Price/Cash flow per share--
Book value per share-0.372
Tangible book value per share-0.372
More ▼

Balance sheet in USDView more

Checkpoint Therapeutics Inc uses little or no debt in its capital structure.
Current ratio0.2647
Quick ratio--
Total debt/total equity--
Total debt/total capital--
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.